Geode Capital Management LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,167,356 shares of the biopharmaceutical company’s stock after buying an additional 52,003 shares during the period. Geode Capital Management LLC owned 0.82% of Amicus Therapeutics worth $8,323,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the stock. UBS Asset Management Americas Inc. boosted its stake in shares of Amicus Therapeutics by 71.8% in the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 21,174 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Amicus Therapeutics by 12.5% in the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 74,700 shares during the last quarter. Princeton Alpha Management LP bought a new stake in shares of Amicus Therapeutics during the first quarter valued at about $106,000. Canada Pension Plan Investment Board bought a new stake in shares of Amicus Therapeutics during the first quarter valued at about $7,346,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Amicus Therapeutics by 51.7% in the first quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock valued at $1,094,000 after buying an additional 52,287 shares during the last quarter.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at 13.10 on Wednesday. The company has a 50-day moving average price of $11.40 and a 200 day moving average price of $8.12. The stock’s market cap is $1.87 billion. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $14.05.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.16 million. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post ($1.44) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/08/02/geode-capital-management-llc-has-8-32-million-position-in-amicus-therapeutics-inc-nasdaqfold.html.
Several analysts have recently issued reports on the company. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Robert W. Baird increased their price objective on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, July 12th. Cowen and Company reiterated a “buy” rating and issued a $16.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $13.42.
In other news, insider Hung Do sold 29,914 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total value of $239,312.00. Following the sale, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the business’s stock in a transaction dated Thursday, July 13th. The stock was bought at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The disclosure for this purchase can be found here. Corporate insiders own 3.40% of the company’s stock.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
